CLINICAL_TRIALS
trial_result
· 2021-12-30
Clinical Trial Update: Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) [Phase 2]
Summary
Phase 2 trial of pamrevlumab (FG-3019) in non-ambulatory Duchenne muscular dystrophy was terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kyntra Bio | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: TERMINATED | Results posted: 2021-12-30